Start with the part used, because the two are not the same kind of thing. Reishi is a fruiting body: the bracket that forms on hardwood is the reproductive structure of Ganoderma lucidum. Chaga is a conk. Inonotus obliquus produces a true fruiting body only briefly, under the bark of a dying birch, and the black material sold as chaga is sterile tissue, fungal hyphae grown through the wood of the colonised tree.
That shapes the chemistry. Fruiting body tissue is mostly fungal cell wall, which is why beta-glucan assays return large figures from reishi. A conk is a mixture: melanin pigment, triterpenes taken up from birch, phenolic acids, and oxalate at the levels recorded in kidney injury cases.
It also shapes what a certificate can report. Reishi can be described by beta-glucan, calculated as total glucan minus alpha-glucan, and by a triterpene figure. Chaga is better described by glucan, phenolics and oxalate. Across this category the usual quality question is fruiting body or mycelium grown on grain, and for chaga the first question is whether the material is conk at all.
Beta-glucan is not measured directly. The accepted enzymatic assay reads total glucan, reads alpha-glucan separately, and gives beta-glucan as the difference. Starch is why that subtraction exists: a crude polysaccharide figure counts alpha-glucan too, so grain substrate carried into a finished powder lifts the headline number without adding beta-glucan.
The genuine figure also shifts with how the mushroom was grown. Ganoderma lucidum fruiting bodies raised on sawdust and chips from five tree species returned 47.5 to 55.9 percent beta-glucan of dry weight on that assay, lowest on pine and highest on aspen. An 8 point spread inside one species, in one laboratory, is the context a single label figure is missing.
Solvent decides the rest. Reishi’s ganoderic acids are lipophilic and come out in alcohol, its beta-glucans are water soluble and come out in hot water, so one extraction returns one fraction. Chaga shows the same effect in numbers: subcritical water at 200 degrees Celsius gave total glucan of 20.4 and 20.9 g per 100 g from two chaga samples, against 0.62 to 1.13 g per 100 g from microwave or ultrasound extraction in 96 percent ethanol.
The gap is not subtle. Reishi’s one positive pooled estimate has an interval crossing no effect, and its glucose and lipid outcomes came back flat. Chaga has no randomised human literature of any kind, and its only human records are kidney injuries.
Reishi is the one with trials: small, clustered in one region and rated poor quality by two Cochrane reviews, with no long-term survival data. If reishi is the choice, look for an extract made with both hot water and alcohol. Chaga has no trial to set against the three kidney injury case reports. Anyone with kidney stones, reduced kidney function or an already high oxalate intake should avoid chaga and speak to a clinician first. Neither carries an authorised claim in Great Britain, so compare them on species, part used, solvent and measured content.
Nothing about health. Under Regulation (EC) 1924/2006 as it applies in Great Britain, a health claim may be used only if it sits on the authorised list, and no claim for reishi, chaga or any functional mushroom appears there. The authorised beta-glucan claims specify oats, oat bran, barley or barley bran at 3 g a day and concern blood cholesterol, so the wording does not transfer to mushroom beta-glucans. What the law allows is description: species, part used, solvent and measured content.
Chaga’s file is a safety file. Three published cases record oxalate nephropathy, all three requiring haemodialysis, with renal function recovering in only one: after 3 g daily for 4 years then 9 g for a year, ending in renal failure; after 4 to 5 teaspoons daily for 6 months; and after 10 to 15 g daily with 500 mg of vitamin C, presenting as nephrotic syndrome with calcium oxalate crystals on biopsy and needing high-dose steroids before kidney function recovered. Avoid chaga with kidney stones or reduced kidney function.
A concentrated fungal extract can fall within Regulation (EU) 2015/2283 on novel foods as it applies in Great Britain, which turns on species, part used and process. Endoca’s CBD range sits on the FSA public list, where applications are recorded rather than approved, and FSA advises no more than 10 mg of CBD a day.
A certificate of analysis sits behind each Endoca mushroom extract, and the quality programme runs pesticide, heavy metal and mycotoxin screening to GMP standards with third party verification. Three figures are missing from it: a beta-glucan percentage, a triterpene content and an oxalate result. For chaga the oxalate figure is the one worth requesting rather than assuming. Endoca works from its own farm, own land and own extraction, since 2010.
Not strictly. Chaga as sold is the sterile conk of Inonotus obliquus: a hard black mass of hyphae grown through birch wood. A true fruiting body does form, briefly and under the bark of a dying tree, but it is not what reaches supplements.
Reishi, although the baseline is low. Two Cochrane reviews pooled 5 randomised trials in cancer patients and 5 in cardiovascular risk, and rated the primary studies poor. No randomised controlled trial of chaga in humans has been published for any outcome.
Its two compound groups need different solvents. The beta-glucans dissolve in water and are drawn out by a hot water decoction. Ganoderic acid triterpenoids are lipophilic and come out in alcohol. A water-only extract is low in triterpenoids, an alcohol-only tincture low in beta-glucans.
One powder analysed in a published case report contained 0.14 g of oxalate per gram, around 14 g per 100 g. Three case reports describe oxalate nephropathy after prolonged chaga intake, all three requiring haemodialysis, with renal function recovering in only one. Case reports cannot establish frequency.
Cortina-Escribano M, Pihlava JM, Miina J, Veteli P, Linnakoski R, Vanhanen H. Effect of strain, wood substrate and cold treatment on the yield and beta-glucan content of Ganoderma lucidum fruiting bodies. Molecules. 2020;25(20):4732.
McCleary BV, Draga A. Measurement of beta-glucan in mushrooms and mycelial products. J AOAC Int. 2016;99(2):364-373.
Jin X, Ruiz Beguerie J, Sze DM, Chan GC. Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database Syst Rev. 2016;(4):CD007731.
Klupp NL, Chang D, Hawke F, Kiat H, Cao H, Grant SJ, Bensoussan A. Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors. Cochrane Database Syst Rev. 2015;(2):CD007259.
Lazic V, Lazic V, Klaus A, Kozarski M, Doroski A, Tosti T, Simic S, Vunduk J. The effect of green extraction technologies on the chemical composition of medicinal chaga mushroom extracts. J Fungi (Basel). 2024;10(3):225.
Lee S, Lee HY, Park Y, Ko EJ, Ban TH, Chung BH, Lee HS, Yang CW. Development of end stage renal disease after long-term ingestion of chaga mushroom: case report and review of literature. J Korean Med Sci. 2020;35(19):e122.
Kikuchi Y, Seta K, Ogawa Y, Takayama T, Nagata M, Taguchi T, Yahata K. Chaga mushroom-induced oxalate nephropathy. Clin Nephrol. 2014;81(6):440-444.
Kwon O, Kim Y, Paek JH, Park WY, Han S, Sin H, Jin K. Chaga mushroom-induced oxalate nephropathy that clinically manifested as nephrotic syndrome: a case report. Medicine (Baltimore). 2022;101(10):e28997.
Ban S, Do TT, Pyo JW, Moon M, Park JT. INO10, a chaga mushroom extract, alleviates Alzheimer’s disease-related pathology and cognitive deficits in 3xTg-AD mice. Int J Mol Sci. 2025;26(10):4729.
Regulation (EU) No 432/2012 establishing a list of permitted health claims made on foods, Annex, beta-glucans entries, as it applies in Great Britain.
Last reviewed 1 October 2026.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.